Top

Published in:

07-09-2023 | Breast Cancer | Breast Oncology

De-escalation of Post-mastectomy Irradiation in Hormone Receptor-Positive Breast Cancer with One to Three Positive Nodes

Authors: Gili G. Halfteck, MD, PhD, Y. Efstathia Polychronopoulou, MSc, Waqar Haque, MD, MS, Roi Weiser, MD, Sandra S. Hatch, MD, V. Suzanne Klimberg, MD, PhD, MSHCT

Published in: Annals of Surgical Oncology | Issue 13/2023

Abstract

Background

The 21-gene recurrence score (RS) is used to predict benefit from chemotherapy in hormone receptor (HR)-positive breast cancer with one to three positive lymph nodes. Prospective–retrospective studies have shown that the RS is prognostic for both systemic and locoregional recurrence in tamoxifen-treated patients. We aimed to assess whether RS could be utilized to predict a survival benefit from postmastectomy radiation therapy (PMRT).

Patients and Methods

The National Cancer Database (NCDB) was used to identify women ≤ 75 years of age with HR+, HER2-negative, T1–3, N1, M0 breast cancer who underwent mastectomy and axillary staging with available RS during the years 2010–2016. Kaplan–Meier and Cox proportional hazards models were used to identify association between treatment and overall survival (OS). Univariate and multivariate analyses were used to identify variables correlating with PMRT and OS.

Results

A total of 8907 patients were identified. Of the total, 3203 (36%) patients received adjuvant PMRT and 5704 (64%) did not. Across the entire cohort, 5-year OS was 97.5% for patients receiving PMRT and 96.8% for those who did not (P = 0.063). After adjusting for all covariates, in patients with RS ≤ 25, there was no statistically significant improvement in 5-year OS with the addition of adjuvant PMRT (97.5% versus 98.1% P = 0.093). Moreover, no survival benefit was seen with axillary node dissection (P = 0.58) or with the addition of chemotherapy (P = 0.312).

Conclusions

In our cohort of patients with one to three positive nodes and a RS ≤ 25, omission of post-mastectomy radiation therapy had no impact on OS. Our results suggest that RS may be utilized in the individualized decision making on PMRT.

Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997. https://doi.org/10.1056/NEJM199710023371401.CrossRefPubMed

Overgaard M, Jensen M-B, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breastcancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999. https://doi.org/10.1016/S0140-6736(98)09201-0.CrossRefPubMed

Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997. https://doi.org/10.1056/NEJM199710023371402.CrossRefPubMed

Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2016.69.1188.CrossRefPubMed

Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1415369.CrossRefPubMed

Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015. https://doi.org/10.1056/NEJMoa1415340.CrossRefPubMedPubMedCentral

McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014. https://doi.org/10.1016/S0140-6736(14)60488-8.CrossRefPubMed

Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004. https://doi.org/10.1056/NEJMoa041588.CrossRefPubMed

Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2108873.CrossRefPubMedPubMedCentral

10.

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018. https://doi.org/10.1056/NEJMoa1804710.CrossRefPubMedPubMedCentral

11.

Weiser R, Polychronopoulou E, Kuo Y-F, et al. De-escalation of endocrine therapy in early hormone receptor-positive breast cancer: when is local treatment enough? Ann Surg. 2021. https://doi.org/10.1097/SLA.0000000000005064.CrossRefPubMed

12.

Mamounas EP, Liu Q, Paik S, et al. 21-Gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw259.CrossRefPubMedPubMedCentral

13.

Woodward WA, Barlow WE, Jagsi R, et al. Association between 21-gene assay recurrence score and locoregional recurrence rates in patients with node-positive breast cancer. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2019.5559.CrossRefPubMedPubMedCentral

14.

Jayasekera J, Schechter CB, Sparano JA, et al. CISNET-BOLD collaborative group effects of radiotherapy in early-stage, low-recurrence risk, hormone-sensitive breast cancer. J Natl Cancer Inst. 2018. https://doi.org/10.1093/jnci/djy128.CrossRefPubMedPubMedCentral

15.

Mallin K, Browner A, Palis B, et al. Incident cases captured in the national cancer database compared with those in US population based central cancer registries in 2012–2014. Ann Surg Oncol. 2019. https://doi.org/10.1245/s10434-019-07213-1.CrossRefPubMed

16.

Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992. https://doi.org/10.1016/0895-4356(92)90133-8.CrossRefPubMed

17.

Weiser R, Haque W, Polychronopoulou E, et al. The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis. Breast Cancer Res Treat. 2021. https://doi.org/10.1007/s10549-020-05971-1.CrossRefPubMed

18.

Cuzick J, Stewart H, Peto R, et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 1987;71(1):15–29.PubMed

19.

Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994. https://doi.org/10.1200/JCO.1994.12.3.447.CrossRefPubMed

20.

Fowble B, Gray R, Gilchrist K, Goodman RL, Taylor S, Tormey DC. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol. 1988. https://doi.org/10.1200/JCO.1988.6.7.1107.CrossRefPubMed

21.

Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001. https://doi.org/10.1200/JCO.2001.19.5.1539.CrossRefPubMed

22.

Bazan JG, Majithia L, Quick AM, et al. Heterogeneity in outcomes of pathologic T1–2N1 breast cancer after mastectomy: looking beyond locoregional failure rates. Ann Surg Oncol. 2018. https://doi.org/10.1245/s10434-018-6565-8.CrossRefPubMed

23.

Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010. https://doi.org/10.1200/JCO.2009.23.7610.CrossRefPubMedPubMedCentral

24.

Plichta JK, Rushing CN, Lewis HC, et al. Implications of missing data on reported breast cancer mortality. Breast Cancer Res Treat. 2023. https://doi.org/10.1007/s10549-022-06764-4.CrossRefPubMed

Title: De-escalation of Post-mastectomy Irradiation in Hormone Receptor-Positive Breast Cancer with One to Three Positive Nodes
Authors: Gili G. Halfteck, MD, PhD
Y. Efstathia Polychronopoulou, MSc
Waqar Haque, MD, MS
Roi Weiser, MD
Sandra S. Hatch, MD
V. Suzanne Klimberg, MD, PhD, MSHCT
Publication date: 07-09-2023
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Mastectomy
Cytostatic Therapy
Published in: Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14155-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

De-escalation of Post-mastectomy Irradiation in Hormone Receptor-Positive Breast Cancer with One to Three Positive Nodes

Abstract

Background

Patients and Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 13/2023

ASO Author Reflections: Preventing Nephrotoxicities in Ovarian Cancer Patients Undergoing HIPEC

There is More than One Way to Skin a Cat

ASO Visual Abstract: Exploring Breast Surgeons’ Attitudes on Universal Genetic Testing: A Qualitative Study

Lymph Node Metastases and Associated Recurrence-Free Survival in Microsatellite Stable and Unstable Colon Cancer

Letter to the Editor: Comment on: “LI‑RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection”

ASO Author Reflections: CTCs in Patients with Gallbladder Adenocarcinoma